AstraZeneca (LSE/STO/Nasdaq: AZN) released impressive financial results for the first nine months (9M) and third quarter (Q3) of 2025, emphasising strong commercial success and notable advancements in its R&D portfolio.
The corporation reported $43.2 billion in total revenue for the first nine months of the year, up 11% at constant exchange rates (CER). Additionally, Core Earnings Per Share (EPS) increased 15% (CER) to $7.04.
Growth in all therapeutic categories drove the performance, with Oncology leading the way with a 16% increase and Respiratory & Immunology (R&I) with a 13% gain.
Detailed Financial Performance (9M 2025)
- At $43.236 billion, total revenue rose by 11%.
- There was a 13% increase in core operating profit.
- Core EPS reached $7.04, a 15% increase.
- There was a notable 42% increase in reported EPS to $5.10.
For the third quarter (Q3) 2025 (at CER)
- At $15.191 billion, total revenue rose by 10%.
- Core EPS rose 12% to $2.38.
- EPS was reported as $1.64, a 70% increase.
Read More: Amgen Q3 Revenue Jumps 12% to $9.6 Billion, Driven by Strong Volume Growth
Therapy Area and Product Growth
Every significant geographic region saw growth. Revenue was mostly generated by the oncology and biopharmaceutical industries.
Key 9M 2025 Product Revenue (at CER)
- Oncology: Product revenue grew 16% to $18.59 billion
- Imfinzi: $4.317 billion, up 25%.
- Enhertu: $1.976 billion, up 38%.
- Calquence: $2.551 billion, up 10%.
- Tagrisso: $5.352 billion, up 10%.
- CVRM (Cardiovascular, Renal & Metabolism): Product revenue grew 5%.
- Farxiga: $6.345 billion, up 11%.
- R&I (Respiratory & Immunology): Product revenue grew 13%.
- Fasenra: $1.451 billion, up 19%.
- Tezspire: $770 million, up 63%.
R&D Pipeline and Strategic Developments
AstraZeneca highlighted its “unprecedented pipeline delivery,” stating that so far this year, it has received 31 regulatory approvals in key areas and 16 good Phase III readouts.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Recent Pipeline Highlights
- Enhertu: In the DESTINY-Breast05 Phase III trial for early breast cancer, it achieved its main goal.
- Datroway: In the TROPION-Breast02 Phase III trial for triple-negative breast cancer (TNBC), two primary objectives were met.
- Baxdrostat: In the Bax24 Phase III trial for treatment-resistant hypertension, it achieved its main goal.
- Saphnelo: In the TULIP-SC Phase III study for SLE (lupus), it achieved its main goal.
Last Modified:
